| |
| |
|
| Insider
Information: |
Hooper Anthony C |
| Relationship: |
Director |
| City: |
Princeton |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
618,962 |
|
|
Indirect Shares
|
5,248 |
|
|
| Direct
Value |
$79,212,041 |
|
|
|
Indirect Value
|
$219,104 |
|
|
| Total
Shares |
624,210 |
|
|
| Total
Value |
$79,431,145 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
0.0
|
| Percentage
Gain/Loss : |
 58.4%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bristol-Myers Squibb Co |
BMY |
SVP ComOps Pres USJap ... |
2011-05-13 |
203,170 |
2011-05-13 |
5,248 |
Premium* |
|
|
Amgen Inc |
AMGN |
EVP, Global Commercial... |
2018-05-03 |
215,147 |
2011-10-27 |
0 |
Premium* |
|
|
MannKind Corp |
MNKD |
Director |
2024-02-04 |
176,153 |
|
0 |
Premium* |
|
|
Beigene Ltd |
BGNE |
Director |
2022-06-22 |
24,492 |
2021-06-16 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
93 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$93,982 |
D/D |
(598) |
187,973 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-01-31 |
4 |
D |
$154.43 |
$103,159 |
D/D |
(668) |
187,305 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
23,092 |
210,397 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-03-24 |
4 |
D |
$166.04 |
$2,013,733 |
D/D |
(12,128) |
198,482 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2017-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
4,920 |
203,402 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-01-30 |
4 |
D |
$198.00 |
$113,850 |
D/D |
(575) |
203,134 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-01-31 |
4 |
D |
$191.27 |
$124,517 |
D/D |
(651) |
202,483 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-03-07 |
4 |
A |
$0.00 |
$0 |
D/D |
17,638 |
220,121 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-03-23 |
4 |
D |
$176.08 |
$1,550,737 |
D/D |
(8,807) |
211,522 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,508 |
216,030 |
0 |
- |
|
| AMGN |
Amgen Inc |
EVP, Global Commercial Ops. |
• • – |
2018-05-03 |
4 |
D |
$169.43 |
$149,607 |
D/D |
(883) |
215,147 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • – |
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,800 |
7,800 |
0 |
- |
|
| BGNE |
Beigene Ltd |
Director |
– • – |
2022-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
16,692 |
24,492 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US PharmaceuticalsOf |
• – – |
2004-01-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,220 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US PharmaceuticalsOf |
• – – |
2004-01-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
52,245 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2004-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
10,556 |
62,801 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2004-07-09 |
4 |
D |
$24.19 |
$14,200 |
D/D |
(587) |
62,214 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,306 |
71,520 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-06-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,430) |
69,090 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-07-11 |
4 |
D |
$24.82 |
$15,860 |
D/D |
(639) |
68,451 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2005-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
93,451 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2006-03-07 |
4 |
D |
$22.73 |
$42,323 |
D/D |
(1,862) |
115,596 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2006-03-07 |
4 |
A |
$22.73 |
$545,679 |
D/D |
24,007 |
117,458 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US Pharmaceuticals |
• – – |
2006-06-20 |
4 |
D |
$25.48 |
$61,942 |
D/D |
(2,431) |
113,165 |
|
- |
|
| BMY |
Bristol-Myers Squibb Co |
President US PharmaceuticalsOf |
• – – |
2007-05-24 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
6,459 |
|
- |
|
93 Records found
|
|
Page 2 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
